Reuters has people in Bangladesh and interns at their HQ in NYC picking up the full story and trying to make a headline out of it. These guys are not biotech people, and have no business trying to make a full research story out of what Ariad just announced.
There is no bad news here. Anyone who knows mTOR knows these are the side-effects. Just like the miserable side-effects of the multi-billion dollar drug, Avastin.
Wonder when Jonny Come Lately, JPMorgan and the others will be printing their updated "research reports". (too bad they didn't read these forums or they could have made 20% for their clients today - traded as high as 4.80 pre-market).